These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12067547)

  • 21. B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894.
    Takaishi S; Tuchiya N; Sato A; Negishi T; Takamatsu Y; Matsushita Y; Watanabe T; Iijima Y; Haruyama H; Kinoshita T; Tanaka M; Kodama K
    J Antibiot (Tokyo); 1998 Sep; 51(9):805-15. PubMed ID: 9820230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential inhibition of wild-type endothelin-converting enzyme-1 and its mutants.
    Savage P; De Lombaert S; Shimada K; Tanzawa K; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S16-8. PubMed ID: 9595388
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phosphoramidon-sensitive and -insensitive endothelin-converting enzyme in human megakaryoblastic cell lines.
    Hamroun D; Dumas J; Mathieu MN; Launay JM; Chevillard C
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S512-4. PubMed ID: 9595528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH.
    Fahnoe DC; Knapp J; Johnson GD; Ahn K
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S22-5. PubMed ID: 11078325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and synthesis of diversely substituted azacyclic inhibitors of endothelin converting enzyme.
    Hanessian S; Gauchet C; Charron G; Marin J; Nakache P
    J Org Chem; 2006 Mar; 71(7):2760-78. PubMed ID: 16555831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
    De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
    J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for functional endothelin-converting enzyme activity in isolated rat basilar artery: effect of inhibitors.
    Vatter H; Schilling L; Schmiedek P; Ehrenreich H
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S64-7. PubMed ID: 9595402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of a potent and selective endothelin-converting enzyme inhibitor, CGS 35066.
    Jeng AY; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Trapani AJ
    J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S36-9. PubMed ID: 11078330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting ACE and ECE with dual acting inhibitors.
    Hanessian S; Guesné S; Riber L; Marin J; Benoist A; Mennecier P; Rupin A; Verbeuren TJ; De Nanteuil G
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1058-62. PubMed ID: 18160283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor.
    Shetty SS; Savage P; DelGrande D; De Lombaert S; Jeng AY
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S68-70. PubMed ID: 9595403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endothelin-2-converting enzyme from human renal adenocarcinoma cells is a phosphoramidon-sensitive, membrane-bound metalloprotease.
    Shinmi O; Yorimitsu K; Moroi K; Nishiyama M; Sugita Y; Saito T; Inagaki Y; Masaki T; Kimura S
    J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S61-4. PubMed ID: 7510000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors.
    Hou YP; Sun J; Pang ZH; Lv PC; Li DD; Yan L; Zhang HJ; Zheng EX; Zhao J; Zhu HL
    Bioorg Med Chem; 2011 Oct; 19(20):5948-54. PubMed ID: 21925884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
    Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular pharmacology of endothelin converting enzymes.
    Turner AJ; Murphy LJ
    Biochem Pharmacol; 1996 Jan; 51(2):91-102. PubMed ID: 8615890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New non-hydroxamic ADAMTS-5 inhibitors based on the 1,2,4-triazole-3-thiol scaffold.
    Maingot L; Leroux F; Landry V; Dumont J; Nagase H; Villoutreix B; Sperandio O; Deprez-Poulain R; Deprez B
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6213-6. PubMed ID: 20846863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dual endothelin-converting enzyme/neutral endopeptidase inhibitors, CGS 26303 and CGS 26393, on lipopolysaccharide or interleukin-1 beta-stimulated release of endothelin from guinea pig tracheal epithelial cells.
    Pelletier S; Battistini B; Jeng AY; Sirois P
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S10-2. PubMed ID: 9595386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
    Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
    J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats.
    Télémaque S; Emoto N; deWit D; Yanagisawa M
    J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S548-50. PubMed ID: 9595539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [D-Val22]big ET-1[16-38] inhibits endothelin-converting enzyme activity: a promising concept in the prevention of cerebral vasospasm.
    Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
    Neurosurg Rev; 2003 May; 26(2):125-32. PubMed ID: 12962299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.